Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf semaglutide isn't working the way you hoped, you're not imagining things and you're not alone. A plateau, a slower start than expected, or no change at all are common concerns — and each has a different explanation. Most of the time, there's a practical reason and a practical fix, though occasionally the medicine genuinely isn't the right fit. This page walks through the main causes in roughly the order they happen. Because semaglutide (sold as Wegovy for weight management) is a prescription-only medicine, any changes to your dose or treatment plan should be discussed with your prescriber rather than adjusted on your own.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The most common reason semaglutide feels like it isn't working is straightforward: the dose hasn't reached the level where it has a strong effect yet. The titration schedule exists to protect your stomach, not to get you results quickly. The 0.25mg starting dose is there to let your body adjust; most people notice a significant shift in appetite only once they've moved up through 0.5mg and 1mg. The two higher maintenance steps (1.7mg and 2.4mg) are where the clinical trial data on meaningful weight loss was collected.
Before concluding the medicine has failed, ask yourself how long you've been on it and at what dose. If you're still in the titration phase, or only recently reached 2.4mg, it's too early to draw conclusions. A useful reference is how long Wegovy takes to work, the timeline is longer than most people expect, and that's not unusual.
One practical note on timing: if you've just returned from a holiday, had a break in injections over a bank holiday week, or started treatment mid-month, your effective dose weeks may be fewer than the calendar weeks suggest. Gaps in injections can reduce the medicine's steady-state concentration, which matters more than people realise.
Semaglutide works by reducing appetite signals, slowing gastric emptying, and influencing the brain's reward response to food. It doesn't override a significant calorie surplus, poor sleep, or stress-driven eating. These factors won't stop the medicine from working entirely, but they can substantially reduce how much weight you lose.
The most common practical blockers are: eating quickly past the point of fullness (the satiety signal still takes 15–20 minutes to arrive, even on semaglutide); not drinking enough water, which is easy to underestimate when your appetite for everything (including fluids) is suppressed; and alcohol, which adds calories without triggering the same fullness response. High-stress periods or significant sleep disruption raise cortisol in ways that can counteract appetite suppression.
None of this is a character flaw; it's physiology. If you want to read more about what life alongside treatment looks like in practice, the Wegovy overview page covers the lifestyle element alongside the clinical evidence. The NHS's patient information on semaglutide also explains how the medicine works and what supports it.
There is a distinct population of people for whom semaglutide produces less than expected. Genetics, gut microbiome, baseline insulin resistance, and other individual factors all influence GLP-1 receptor sensitivity. This isn't a moral judgement; it's biology, and the clinical trials showed meaningful variation in individual response even at the highest dose.
The NICE threshold is a useful benchmark: if you've been on the maintenance dose for six months and weight loss is below 5%, the guidance recommends a clinical review of whether to continue. At that point, your prescriber might look at whether a different medicine is more appropriate. Some people who plateau on semaglutide see better results on tirzepatide (Mounjaro), which works on two receptor pathways rather than one, this is one of the things a prescriber weighs when investigating why semaglutide isn't working for a specific person.
If you're already on Wegovy and things have stalled specifically at a particular dose, there's a more focused look at what tends to happen when the 5mg semaglutide dose isn't producing results. And if you're wondering whether what you're experiencing is distinct from the injection, the broader Wegovy not working page covers the full picture, including questions about pen technique and storage.
Go back sooner rather than later if: weight has been completely unchanged for more than four weeks at the maintenance dose; you've noticed the appetite suppression you felt early on has faded; you're experiencing side effects that are affecting your ability to take the medicine consistently; or you have concerns about whether the pen was stored or used correctly.
Weight that stays flat for a brief period mid-treatment is different from weight that simply won't move after months at full dose. The former is common. The latter deserves a conversation. If you want to understand how long semaglutide stays active after you stop (relevant if you're considering switching) the page on how long Wegovy takes to leave your system is a helpful reference before that discussion.
For a broader look at what's available if Wegovy isn't the right fit, our weight-loss treatment overview sets out the options, and the cost context for Wegovy is worth reading if affordability is part of the picture. If you'd like a prescriber to review your situation directly, check your eligibility with a free consultation, one of our GPhC-registered prescribers will review your case the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.